

1

Supporting Information

2 **Amino-Functionalized Lanthanide-Organic Framework for Ratiometric** 3 **Detection of ONOO⁻**

4 Huimin Zhuo,^{a#} Xiao Liu,^{a,b#} Congmin Sun,^a Yang Liu,^c Jiaqi Deng,^a Xu He,^a Zhiqiang
5 Li,^{*a} Jing Liang^{*d} and Qingqing Xiong^{*c}

6

7 ^a *School of Chemical Engineering and Technology, Hebei University of Technology, XiPing Dao*
8 *5340, Beichen District, Tianjin 300401, P. R. China.*

9 ^b *School of Material Science and Engineering, Hebei University of Technology, XiPing Dao 5340,*
10 *Beichen District, Tianjin 300401, P. R. China.*

11 ^c *Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer*
12 *Institute & Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of*
13 *Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, P. R. China.*

14 ^d *Tianjin Third Central Hospital, Jintang Road 83, Hedong District, Tianjin 300170, P. R. China*

15

16 ^{*}Corresponding authors. E-mail address: zhiqiangli@hebut.edu.cn (Zhiqiang Li),
17 Haolele77@sina.com (Jing Liang), xionqingqing@tmu.edu.cn (Qingqing. Xiong).

18

19 [#] H. Z. and X. L. contributed equally to this work.

20

1 Experimental Section

2 1. Materials and methods

3 Except for special statements, all reagents were purchased from commercial sources
4 without further purification. 2'-Amino-[1,1':4',1''-terphenyl]-3,3'',5,5''-tetracarboxylic
5 acid (H₄TPTC-NH₂) was obtained from Nanchang Chouhepharm Co., Ltd.
6 Eu(NO₃)₃·6H₂O and Gd(NO₃)₃·6H₂O were purchased from Shanghai Aladdin
7 Biochemical Technology Co., Ltd. Ammonium iron (II) sulfate, Urea, Glucose, NaBr,
8 Na₂CO₃, KCl, MgCl₂, NaHCO₃, CaCl₂, NaOH, Glucose, L-cysteine, NH₄Cl, L-serine,
9 Na₂SO₄, Glutathione, L-proline, and tert-butyl hydroperoxide were purchased from
10 Beijing HWRK Chem Co., Ltd. H₂O₂, H₂SO₄, NaNO₂, L-Threonine, Glycine, Fructose,
11 MnO₂, NaClO, and 3,3'-(naphthalene-1,4-diyl) dipropionic acid were purchased from
12 Anhui Senrise Technology Co., Ltd. N, N-dimethylformamid and ethanol were
13 obtained from Guangshunda Chemical Reagent Co., Ltd (Tianjin, China).

14 ¹H NMR spectra were recorded on a Bruker AVANCE400 instrument at 400Hz,
15 25°C. ¹H NMR sample was prepared as follow: **EuTPTC-NH₂** (6.0 mg) was suspended
16 in 3.0 mL of ONOO⁻ solution (11.2 mM) and incubated in the dark for 6 h. The obtained
17 precipitate was filtered, washed with water and dried under vacuum, then monitored
18 with DMSO-*d*₆ and DCl (5/1, v/v) as the solvent. Liquid chromatograph-mass
19 spectrometer (LC-MS) was recorded on a Bruker Scientific instrument with a negative
20 ionization mode. LC-MS sample was prepared in a similar way to the ¹H NMR sample
21 as expected for the use of acid digestion with hydrochloric acid. Powder X-ray
22 diffraction (PXRD) patterns were carried on an X-ray powder diffractometer (Bruker
23 D8 Focus) complying Cu K α radiation ($\lambda = 1.5418\text{\AA}$), operating at 40 kV and 40 mA.
24 Fourier transform infrared spectrum (FT-IR) was recorded on a Thermo Nicolet 5700
25 FTIR instrument from 4000 to 400 cm⁻¹. X-ray photoelectron spectroscopy (XPS) was
26 obtained from a Shimadzu/Krayos AXIS Ultra DLD spectrometer. The
27 photoluminescence measurements (excitation and emission spectra) were tested by an
28 Edinburgh Instruments FS1000 near-infrared spectrometer, with a 450 W Xenon lamp
29 as the steady-state excitation source, a double excitation monochromator (1800
30 lines·mm⁻¹), an emission monochromator (600 lines·mm⁻¹), a semiconductor cooled

1 Hamamatsu RMP928 photomultiplier tube. UV-Vis spectra were recorded in a quartz
2 cell (light path 10 mm) on an Agilent Carry 100 UV spectrometer.

3

4 **2. Synthesis**

5 Synthesis of ONOO⁻: According to the reported literature,¹ the mixed solution of
6 NaNO₂ (0.6 M, 5 mL) and H₂O₂ (0.7 M, 0.3mL) was reacted with sulfuric acid (0.3 M,
7 80 μL). Next, NaOH (1.5 M, 10 mL) was added quickly (about 2 s) to make the mixture
8 alkaline. The excess hydrogen peroxide was removed by passing the solution through
9 a short column of manganese dioxide. The concentration of ONOO⁻ solution was
10 calibrated by monitoring the absorbance at 302 nm ($\epsilon = 1670 \text{ M}^{-1} \text{ cm}^{-1}$) in NaOH (0.1
11 M, 3 mL). The resulting solution was split into small aliquots and stored at lower than -
12 18°C. The aliquots were thawed immediately before use, and the concentration of
13 ONOO⁻ was determined by measuring the absorption of the solution at 302 nm.

14 Synthesis of ·OH: According to the reported literature,² it was made from a mixture
15 of H₂O₂ and 10 equiv. (NH₄)₂Fe(SO₄)₂.

16 Synthesis of ¹O₂: According to the reported literature,³ singlet oxygen was generated
17 from 3,3'-(naphthalene-1,4-diyl)dipropionic acid (10 mM).

18 Synthesis of **EuTPTC-NH₂**: According to the reported literature,⁴ 2'-amino-
19 [1,1':4',1''-terphenyl]-3,3'',5,5''-tetracarboxylic acid (21.0 mg, 0.05 mmol) and
20 Eu(NO₃)₃·6H₂O (75.0 mg, 0.168 mmol) were dissolved in the mixture of 2.5 mL DMF,
21 1.5 mL deionized water and 25 μL H₂SO₄ in a Teflon vessel in a stainless steel
22 autoclave, then placed in an oven at 90°C for 3 d. It was cooled to room temperature,
23 yellow clustered crystals can be separated out. The crystals were collected and washed
24 with deionized water three times and dried under vacuum at 50°C overnight. The
25 **GdTPTC-NH₂** was synthesized similarly to **EuTPTC-NH₂** expect for the use of
26 Gd(NO₃)₃·6H₂O. The **EuTPTC** was synthesized similarly to **EuTPTC-NH₂** expect for
27 the use of [1,1':4',1''-terphenyl]-3,3'',5,5''-tetracarboxylic acid.

28

29 **3. Determination of ONOO⁻**

1 The emission spectra of **EuTPTC-NH₂** saline suspension (0.02 mg/mL) were
2 measured after adding different concentration of ONOO⁻ and waiting 50 s ($\lambda_{\text{ex}} = 313$
3 nm). This procedure was repeated three times with three different **EuTPTC-NH₂**.

4

5 **4. Selectivity and anti-interference experiments**

6 The selective experiment was as follow: the emission spectra of **EuTPTC-NH₂**
7 saline suspension (0.02 mg/mL) after adding ONOO⁻ (112 μM) or other substances
8 were recorded, including biologically relevant RNS, peroxide, and reactive oxygen
9 species (ClO⁻, H₂O₂, NO₂⁻, ¹O₂, $\cdot\text{OH}$, and tert-butyl hydroperoxide). The anti-
10 interference experiment was as follow: the emission spectra of **EuTPTC-NH₂** saline
11 suspension (0.02 mg/mL) simultaneously upon addition of ONOO⁻ (112 μM) and serum
12 components were recorded, including urea, glucose, L-serine, L-threonine, glycine,
13 NH₄Cl, NaCl, MgCl₂, CaCl₂, KCl, MgSO₄, Na₂SO₄, Na₂HCO₃, NaH₂CO₃ and
14 Na₂HPO₄.

15

16 **5. Establishment of acetaminophen (APAP)-induced acute liver injury (ALI)** 17 **model**

18 Female C57/BL6 mice (18-20 g) were purchased from SiPeiFu Biotechnology Co.,
19 Ltd. (Beijing, China). The mouse liver injury model was established by intraperitoneal
20 injection of APAP. Briefly, APAP was dissolved in warm saline at a concentration of
21 20 mg/mL. Mice were fasted overnight and then injected intraperitoneally with APAP
22 at a dose of 300 mg/kg. Mice injected with saline were used as the control group. After
23 8 h, the mice were anaesthetised, blood was collected and serum was separated for
24 photoluminescence testing. The remaining serum was used for biochemical tests to
25 assess the liver function of the mice. Liver tissues were harvested for pathological
26 evaluation by hematoxylin-eosin staining. All the protocols were approved by the
27 Animal Care and Use Committee of the Animal Ethical and Welfare Committee of
28 Tianjin Medical University Cancer Institute & Hospital (Approval No. 2024051).

29

30 **6. Clinical Samples**


1 Healthy human serum was separated from blood left over from a medical
2 examination of a healthy donor from Cancer Prevention Center of Tianjin Medical
3 University Cancer Institute & Hospital. Liver injury serum samples were obtained from
4 the remainder of routine laboratory tests on clinical patients diagnosed with drug-
5 induced liver injury (DILI) from Tianjin Third Central Hospital. All the protocols were
6 approved by the Ethics Committee of Tianjin Medical University Cancer Institute &
7 Hospital (Approval No. bc20241742), and the informed consents were obtained.

8

9 **7. Detection of ONOO⁻ in biological environments**

10 A **EuTPTC-NH₂** suspension (0.02 mg/mL) was prepared by replacing saline with
11 mice serum and human serum, and the emission spectra were recorded with the addition
12 of different concentration of ONOO⁻ ($\lambda_{\text{ex}} = 313 \text{ nm}$). This procedure was repeated three
13 times with three different **EuTPTC-NH₂**. The measurements were plugged into the
14 equation of the standard curve to get the apparent concentration values which were
15 obtained the ONOO⁻ concentration data in the original serum specimens. After that,
16 different concentrations of ONOO⁻ were added into the serum samples to further assess
17 the reliability of **EuTPTC-NH₂**. The recoveries of ONOO⁻ in mice and human serum
18 samples were calculated.


1 **8. Supplementary Figures and Tables**



2

3 **Fig. S1.** Optical microscope image of the **EuTPTC-NH₂** crystal.


4



5

6 **Fig. S2.** UV-Vis absorption spectrum of **EuTPTC-NH₂** suspension.


7



1

2 **Fig. S3.** Normalized excitation ($\lambda_{\text{mon}} = 410 \text{ nm}$) (left) and emission ($\lambda_{\text{ex}} = 313 \text{ nm}$)
 3 (right) spectra of $\text{H}_4\text{TPTC-NH}_2$.

4




5

6 **Fig. S4.** PXRD patterns of EuTPTC-NH_2 in acidic and alkaline aqueous solution (pH


1 0-14) for 6 h.

2



4 **Fig. S5.** (a) Emission spectra of **EuTPTC-NH₂** after immersion in acidic and alkaline
5 aqueous solution (pH 2-12) for 6 h. ($\lambda_{\text{ex}} = 313$ nm). (b) Emission intensity ratio (I_{410}/I_{616})
6 of **EuTPTC-NH₂** at different pH in the range of 2-12.

7



9 **Fig. S6.** (a) Emission spectra of **EuTPTC-NH₂** suspension in saline for different
10 periods ($\lambda_{\text{ex}} = 313$ nm). (b) Emission intensity ratio (I_{410}/I_{616}) of **EuTPTC-NH₂** at
11 different periods.





12






13 **Table S1.** The Lab values (L1*, a1*, b1*, L2*, a2*, and b2*) of ratiometric probes.


Name	L1*	a1*	b1*	L2*	a2*	b2*
4-MB	18	20	-50	94	-31	-8

MITO-CC	37	46	-24	38	-17	-23
CS-ONOO	35	-23	25	15	32	18
CPC	21	-11	12	16	29	18
AHC	33	36	-84	67	58	-6
Mito-NA	11	10	-36	41	-3	33
PTZ-H	33	38	34	47	39	-39
HBT-FI-BnB	47	39	-37	85	3	73
NpRh-ONOO	53	-14	-5	68	-2	5
F ₄₈₂	55	77	66	48	-20	28
ABAH-LW	9	20	-39	60	-21	18
RTFP	54	-13	-6	70	-3	5
3a	49	22	14	58	-25	-28
CHCN	36	23	13	41	-10	-6
MG-ONOO	23	2	-37	29	36	-13
Mito-CM-CD	23	36	-36	38	6	-44
NX	2	12	-32	37	23	6
GYP	84	1	27	40	64	42
CSU-FT	22	24	-36	81	6	30
NTC	20	31	-21	45	-35	4
EuTPTC-NH₂	46	70	5	21	54	-89

Table S2. Comparison of ratiometric probes in terms of structure/ligand, linear range, LOD and ΔE_{ab}^* .

Structure/Ligand	Categorization	Name	Range (μM)	LODs (μM)	ΔE_{ab}^*	Ref.
	Small molecule luminescent probe	Cy-NEt ₂	0.5-1.5	0.17	-	5
		4-MB	0-10	0.0298	101	6
		MITO-CC	0-7.5	0.0113	63	7
		3-HF-OMe	0-2.5	0.0655	-	8

	3-HF- PhMe	0-5	0.021	-	
	3-HF-Ph	0-5	0.2556	-	
	CS-ONOO	0-50	0.059	59	9
	CPC	0-18	0.016	41	10
	AHC	5-6	0.0018	88	11




Mito-NA

0-30

0.12

104

12




PTZ-H

0-30

0.021

74

13




HBT-FI-BnB

0-25

2.1

12

14




MULTI-ONOO

0-20

0.0116

-

15




NpRh-ONOO

0-1

0.00333

22

16




PNCy3Cy5

0-0.7

0.00065

-

17




F₄₈₂

0-20

0.15054

104

18




ABAH-LW

0-10

0.0214

69

19




RTFP

0-7

0.0041

22

20




3a

0-2

0.0194

50

21




CHCN

0-25

0.0497

38

22




RTP-PN

0-1.4

0.0014

-

23




RH-PN

0-18

0.093

-

24




MO-E1

0-3.5

0.8

-

25




MO-E2

0-2.5

6.53

-




MO-E3

0-8

0.28

-




JQ-2

5-9

5.3

-

26




WND-1

0-50

0.93

-

27




MG-ONOO

0-2

0.013

61

28




Mito-CM-CD

2-7

0.0429

34

29




K-ONOO

0-15

0.212

-

30




CD-NA

0-200

0.015

-

31




NX

15-40

0.082

53

32






GYP


0-15

0.27

78

33

	Ir ³⁺ -complex	Ir-CBM	0-40	0.093	-	34
	Ru ³⁺ -complex	Ru-Cy5	0-30	0.28	-	35
	Polymer probe	PB-PVA	0-6	0.3	-	36
-	Multicolor fluorescent nanoprobe	CSU-FT	0-1	0.0117	90	37
-	Near-infrared ratiometric fluorescent	NTC	0-1 1-30	0.0153	75	38



nanoprobe

-

Nanoprobe

PA

0-10

0.1

-

39

Lanthanide-
doped

UCNPs@PEI@E-
CC

0-90

0.154

-

40

-

Upconversion
nanoprobes

UCNPs@PEI@H-
CC

0-100

0.241

-

EuTPTC-NH₂

0-11

0.0053

100

(in saline)

Lanthanide
metal-organic
frameworks

EuTPTC-NH₂

0-3

0.0173

-

This
work

(in mice serum)

EuTPTC-NH₂


0-2

0.0291

-

(in human serum)


1



2

3 **Fig. S7.** Emission spectra of **EuTPTC-NH₂** suspension (0.02 mg/mL) in the presence
 4 of different interferents ($\lambda_{\text{ex}} = 313$ nm).


5



6


7 **Fig. S8.** Normalized excitation ($\lambda_{\text{mon}} = 616$ nm) (left) and emission ($\lambda_{\text{ex}} = 313$ nm)
 8 (right) spectra of **EuTPTC**, inset: the corresponding photographic images under 365
 9 nm UV light (upper) and daylight (lower).

10




1
 2 **Fig. S9.** (a) Emission spectra of **EuTPTC** suspension (0.02 mg/mL) in saline upon
 3 addition of ONOO^- (0-140 μM) ($\lambda_{\text{ex}} = 313$ nm). (b) Changes in the emission intensity
 4 ratio (I_{410}/I_{616}) of **EuTPTC** upon addition of ONOO^- in saline ($\lambda_{\text{ex}} = 313$ nm).

5




6
 7 **Fig. S10.** Emission decay profiles of **EuTPTC-NH₂** suspension before (i) and after (ii)
 8 adding 112 μM ONOO^- (excited at 313 nm and monitored at 616 nm).



1

2 **Fig. S11.** FT-IR spectra of **EuTPTC-NH₂** before (i) and after (ii) adding **ONOO⁻**.


3



4

5 **Fig. S12.** Emission spectra of **H₄TPTC-NH₂** suspension in saline upon addition of
6 **ONOO⁻** (0-24 μM) ($\lambda_{\text{ex}} = 313 \text{ nm}$).

7




1

2 **Fig. S13.** Solid-state UV-Vis absorption spectra of $H_4TPTC-NH_2$ before (a) and after
 3 (b) adding $ONOO^-$.

4

5 According to Reinhoudt's empirical rule,⁴¹ intersystem crossing process (ISC) is
 6 effective when the energy gap between S_1 and T_1 of the ligand is greater than 5000 cm^{-1} .


7



8

9 **Fig. S14.** PXRD patterns of $GdTPTC-NH_2$ and $EuTPTC-NH_2$.

10



1
2 **Fig. S15.** Phosphorescence spectra of **GdTPTC-NH₂** before (a) and after (b) adding
3 **ONOO⁻** at 77 K.

4
5 The triplet energy level (T_1) of the ligand $H_4TPTC-NH_2$ was calculated to be 22883
6 cm^{-1} , higher than 5D_0 (17500 cm^{-1}) of Eu^{3+} , which confirmed $H_4TPTC-NH_2$ is an
7 “antenna chromophore” to sensitize Eu^{3+} ions.⁴²

8
9 **Table S3.** Serum biochemical assay data for samples from healthy and liver-injured
10 mice (The abnormal indicator values are marked in red).

Indicators	Normal reference range (U/L)	Healthy mouse (U/L)	ALI mouse-1 (U/L)	ALI mouse-2 (U/L)	ALI mouse-3 (U/L)
ALT	10.06-96.47	45.320	850.953	1026.314	1779.76
AST	36.31-235.48	174.390	377.483	645.891	2395.645

11
12
13 **Table S4.** Quantification of **ONOO⁻** in mice serum samples with RSD (n = 3).

Samples	Added (μM)	Found (μM)	Recovery (%)	RSD (%)
	0	0.67±0.01	-	1.50
Healthy mouse	2	2.71±0.04	101.50	1.50
	4	4.74±0.06	101.50	1.17
	6	6.83±0.05	102.5	0.67

	0	76.83±0.05	-	0.11
ALI mouse-1	2	78.90±0.05	103.50	0.05
	4	80.85±0.07	100.50	0.09
	6	82.89±0.05	101.00	0.06
	0	78.91±0.05	-	0.05
ALI mouse-2	2	80.85±0.07	97.00	0.07
	4	82.92±0.05	100.25	0.05
	6	84.87±0.12	99.33	0.12
	0	87.82±0.06	-	0.06
ALI mouse-3	2	89.83±0.05	100.50	0.06
	4	91.80±0.03	99.50	0.03
	6	93.91±0.04	101.50	0.04

Table S5. Routine blood parameters and serum biochemical assay data for healthy donor and clinical patients with DILI (The abnormal indicator values are marked in red).

Indicators	Normal reference range	Unit	Healthy donor	DILI patient-1	DILI patient-2	DILI patient-3
Gender	-	-	Female	Male	Female	Female
WBC	3.5-9.5	×10 ⁹ /L	4.21	3.2	3.44	4.06
HGB	130-175	g/L	137	135	103	125
	115-150					
HCT	40-50	%	41.6	39.6	31.1	36.6
	35-45					
PLT	125-350	×10 ⁹ /L	175	127	124	157
ALT	0-40	U/L	10	257	70	276
AST	0-42	U/L	14	196	374	1539
ALP	40-150	U/L	54	62	139	193
γ-GT	10-60	U/L	20	123	120	170

TBIL	0-23	μmol/L	11.7	165.2	165.3	129.9
TP	60-80	g/L	69.3	59.6	57.5	72.6
ALB	40-55	g/L	47.3	37.7	34.5	39.1
GLB	20-40	g/L	22	21.9	23	33.5
BUN	1.8-7.1	mmol/L	4.4	4.4	5.12	4.01
CREA	57-111 (males)	μmol/L	66	66	53	42
	41-81 (females)					
UA	210-430 (males)	μmol/L	270	207	246	277
	150-360 (females)					

WBC: white blood cells; HGB: hemoglobin; HCT: hematocrit; PLT: blood platelet; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; γ-GT: γ-glutamyl transpeptidase; TBIL: total bilirubin; TP: total protein; ALB: albumin; GLB: globularproteins; BUN: blood urea nitrogen; CREA: creatinine; UA: uric acid

1 References

- 2 1. L. Wu, J. Liu, X. Tian, R. R. Groleau, B. Feng, Y. Yang, A. C. Sedgwick, H. H.
3 Han, Y. Wang, H. M. Wang, F. Huang, S. D. Bull, H. Zhang, C. Huang, Y.
4 Zang, J. Li, X. P. He, P. Li, B. Tang, T. D. James and J. L. Sessler, *J. Am. Chem.*
5 *Soc.*, 2022, **144**, 174-183.
- 6 2. Z. Song, D. Mao, S. H. P. Sung, R. T. K. Kwok, J. W. Y. Lam, D. Kong, D. Ding
7 and B. Z. Tang, *Adv. Mater.*, 2016, **28**, 7249-7256.
- 8 3. P. Wang, L. Yu, J. Gong, J. Xiong, S. Zi, H. Xie, F. Zhang, Z. Mao, Z. Liu and
9 J. S. Kim, *Angew. Chem., Int. Ed.*, 2022, **61**, e202206894.
- 10 4. K. Yu, Q. Wang, W. Xiang, Z. Li, Y. He and D. Zhao, *Inorg. Chem.*, 2022, **61**,
11 13627-13636.
- 12 5. D. Y. Zhou, Y. Li, W. L. Jiang, Y. Tian, J. Fei and C. Y. Li, *Chem. Commun.*,
13 2018, **54**, 11590-11593.
- 14 6. S. Palanisamy, P. Y. Wu, S. C. Wu, Y. J. Chen, S. C. Tzou, C. H. Wang, C. Y.
15 Chen and Y. M. Wang, *Biosens. Bioelectron.*, 2017, **91**, 849-856.
- 16 7. D. Cheng, Y. Pan, L. Wang, Z. Zeng, L. Yuan, X. Zhang and Y. T. Chang, *J. Am.*
17 *Chem. Soc.*, 2017, **139**, 285-292.
- 18 8. A. C. Sedgwick, W. T. Dou, J. B. Jiao, L. Wu, G. T. Williams, A. T. A. Jenkins,
19 S. D. Bull, J. L. Sessler, X. P. He and T. D. James, *J. Am. Chem. Soc.*, 2018,
20 **140**, 14267-14271.
- 21 9. S. Feng, D. Liu and G. Feng, *Anal. Chim. Acta*, 2019, **1054**, 137-144.
- 22 10. Y. Shen, L. Dai, Y. Zhang, H. Li, Y. Chen and C. Zhang, *Spectrochim. Acta,*
23 *Part A*, 2020, **228**, 117762.
- 24 11. X. Gong, D. Cheng, W. Li, Y. Shen, R. Peng, L. Shi, L. He and L. Yuan, *J.*
25 *Mater. Chem. B*, 2021, **9**, 8246-8252.
- 26 12. J. Cui, S. Zang, H. Nie, T. Shen, S. Su, J. Jing and X. Zhang, *Sens. Actuators, B*,
27 2021, **328**, 129069.
- 28 13. T. Huang, S. Yan, Y. Yu, Y. Xue, Y. Yu and C. Han, *Anal. Chem.*, 2022, **94**,
29 1415-1424.
- 30 14. Z. Wang, M. Yan, M. Yu, G. Zhang, W. Fang and F. Yu, *Anal. Chem.*, 2024, **96**,
31 3600-3608.
- 32 15. W. Xu, Q. Yang, J. Zeng, L. Tan, L. Zhou, L. Peng, Y. Zhou, C. Xie, K. Luo and
33 Z. Zhang, *Sens. Actuators, B*, 2022, **359**, 131565.

- 1 16. S. G. Sun, H. Ding, G. Yuan and L. Zhou, *Anal. Chim. Acta*, 2020, **1100**, 200-
2 207.
- 3 17. X. Jia, Q. Chen, Y. Yang, Y. Tang, R. Wang, Y. Xu, W. Zhu and X. Qian, *J. Am.*
4 *Chem. Soc.*, 2016, **138**, 10778-10781.
- 5 18. Z. Li, S. H. Yan, C. Chen, Z. R. Geng, J. Y. Chang, C. X. Chen, B. H. Huang and
6 Z. L. Wang, *Biosens. Bioelectron.*, 2017, **90**, 75-82.
- 7 19. L. Wu, Y. Wang, M. Weber, L. Liu, A. C. Sedgwick, S. D. Bull, C. Huang and T.
8 D. James, *Chem. Commun.*, 2018, **54**, 9953-9956.
- 9 20. D. Cheng, X. Gong, Q. Wu, J. Yuan, Y. Lv, L. Yuan and X. Zhang, *Anal. Chem.*,
10 2020, **92**, 11396-11404.
- 11 21. J. T. Hou, B. Wang, Y. Zhang, B. Cui, X. Cao, M. Zhang, Y. Ye and S. Wang,
12 *Chem. Commun.*, 2020, **56**, 2759-2762.
- 13 22. X. Zhou, Y. Kwon, G. Kim, J. H. Ryu and J. Yoon, *Biosens. Bioelectron.*, 2015,
14 **64**, 285-291.
- 15 23. Z. Wang, L. Wu, Y. Wang, M. Zhang, Z. Zhao, C. Liu, Q. Duan, P. Jia and B.
16 Zhu, *Anal. Chim. Acta*, 2019, **1049**, 219-225.
- 17 24. P. Jia, Z. Zhuang, C. Liu, Z. Wang, Q. Duan, Z. Li, H. Zhu, F. Zhang, W. Sheng
18 and B. Zhu, *Dyes Pigm.*, 2020, **173**, 107942.
- 19 25. M. L. Odyniec, S. J. Park, J. E. Gardiner, E. C. Webb, A. C. Sedgwick, J. Yoon,
20 S. D. Bull, H. M. Kim and T. D. James, *Chem. Sci.*, 2020, **11**, 7329-7334.
- 21 26. J. Q. Xu, M. J. Gao, J.S. Guo, Y. H. Wang, R. Wei, Y. L. Meng and Y. F. Kang,
22 *Bioorg. Chem.*, 2022, **128**, 106055.
- 23 27. Y. Liu, Y. Ma and W. Lin, *Sens. Actuators, B*, 2022, **373**, 132742.
- 24 28. S. Feng, Z. Zheng, S. Gong and G. Feng, *Sens. Actuators, B*, 2022, **361**, 131751.
- 25 29. C. Jing, Y. Wang, X. Song, X. Li, Y. Feng, M. Kou, G. Zhang, W. Dou and W.
26 Liu, *Sens. Actuators, B*, 2022, **365**, 131847.
- 27 30. H. Kang, W. Shu, J. Yu, M. Gao, R. Han, J. Jing, R. Zhang and X. Zhang, *Sens.*
28 *Actuators, B*, 2022, **359**, 131393.
- 29 31. Y. Liu, J. Zhao and Y. Wang, *Org. Biomol. Chem.*, 2024, **22**, 159-168.
- 30 32. X. Hou, Y. Xue, C. Liu, Z. Li and Z. Xu, *Spectrochim. Acta, Part A*, 2024, **320**,
31 124665.
- 32 33. G. Lu, H. Fan, K. Wang, G. Tian, C. Chen, Y. Wang, L. Wang and X. Fan,
33 *Talanta*, 2024, **267**, 125157.
- 34 34. X. Gao, W. Zhang, Z. Dong, J. Ren, B. Song, R. Zhang and J. Yuan, *Anal.*

- 1 *Chem.*, 2023, **95**, 18530-18539.
- 2 35. W. Zhang, Y. Liu, Q. Gao, C. Liu, B. Song, R. Zhang and J. Yuan, *Chem.*
3 *Commun.*, 2018, **54**, 13698-13701.
- 4 36. H. K. Lao, J. Tan, C. Wang and X. Zhang, *Molecules*, 2019, **24**, 3465.
- 5 37. W. Xu, L. Tan, J. Zeng, Q. Yang, Y. Zhou and L. Zhou, *Biosens. Bioelectron.*,
6 2022, **209**, 114242.
- 7 38. C. Xie, Y. Zhou, K. Luo, Q. Yang, L. Tan and L. Zhou, *Anal. Chem.*, 2022, **94**,
8 15518-15524.
- 9 39. J. Zhang, X. Zhen, P. K. Upputuri, M. Pramanik, P. Chen and K. Pu, *Adv. Mater.*,
10 2017, **29**, 1604764.
- 11 40. X. Liu, H. Lai, J. Peng, D. Cheng, X. B. Zhang and L. Yuan, *Small*, 2019, **15**,
12 1902737.
- 13 41. F. J. Steemers, W. Verboom, D. N. Reinhoudt, E. B. van der Tol and J. W.
14 Verhoeven, *J. Am. Chem. Soc.*, 1995, **117**, 9408-9414.
- 15 42. T. Feng, Y. Ye, X. Liu, H. Cui, Z. Li, Y. Zhang, B. Liang, H. Li and B. Chen,
16 *Angew. Chem., Int. Ed.*, 2020, **59**, 21752-21757.
- 17